BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20506333)

  • 1. Sirolimus versus paclitaxel coronary stents in clinical practice.
    Millauer N; Jüni P; Hofmann A; Wandel S; Bhambhani A; Billinger M; Urwyler N; Wenaweser P; Hellige G; Räber L; Cook S; Vogel R; Togni M; Seiler C; Meier B; Windecker S
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):5-12. PubMed ID: 20506333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
    JACC Cardiovasc Interv; 2011 Mar; 4(3):310-6. PubMed ID: 21435609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
    Novack V; Cutlip D; Kleiman N; Pencina M; Mauri L; Yen CH; Berger P; Goldberg S; Kellett M; Waksman R; Hong M; Raizner AE; Cohen DJ
    JACC Cardiovasc Interv; 2009 Aug; 2(8):767-75. PubMed ID: 19695546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients.
    Birkmeier KA; Kastrati A; Byrne RA; Holle H; Schulz S; Tiroch K; Kufner S; Massberg S; Laugwitz KL; Schömig A; Mehilli J
    Catheter Cardiovasc Interv; 2011 Mar; 77(4):494-501. PubMed ID: 20824758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: prospective randomized multicenter trial.
    Hong SJ; Kim MH; Cha KS; Park HS; Chae SC; Hur SH; Gwon HC; Bae JH; Lim DS
    Catheter Cardiovasc Interv; 2010 Dec; 76(7):924-33. PubMed ID: 20815045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus- versus paclitaxel-eluting stents for the treatment of cardiac allograft vasculopathy.
    Lee MS; Tarantini G; Xhaxho J; Yang T; Ehdaie A; Bhatia R; Favaretto E; Tobis J
    JACC Cardiovasc Interv; 2010 Apr; 3(4):378-82. PubMed ID: 20398863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
    Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
    JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel versus sirolimus eluting stents in diabetic patients: does stent type and/or stent diameter matter?: long-term clinical outcome of 2,429-patient multicenter registry.
    Tarantini G; Facchin M; Capodanno D; Musumeci G; Saia F; Menozzi A; Meliga E; Mancone M; Lettieri C; Tamburino C
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):80-9. PubMed ID: 22511311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation.
    Cho Y; Yang HM; Park KW; Chung WY; Choi DJ; Seo WW; Jeong KT; Chae SC; Lee MY; Hur SH; Chae JK; Seong IW; Yoon JH; Oh SK; Kim DI; Park KS; Rha SW; Jang YS; Bae JH; Hong TJ; Cho MC; Kim YJ; Jeong MH; Kim MJ; Park SK; Chae IH; Kim HS;
    JACC Cardiovasc Interv; 2010 May; 3(5):498-506. PubMed ID: 20488406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial.
    Togni M; Eber S; Widmer J; Billinger M; Wenaweser P; Cook S; Vogel R; Seiler C; Eberli FR; Maier W; Corti R; Roffi M; Lüscher TF; Garachemani A; Hess OM; Wandel S; Meier B; Jüni P; Windecker S
    J Am Coll Cardiol; 2007 Sep; 50(12):1123-31. PubMed ID: 17868802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus- versus paclitaxel-eluting stents for coronary bifurcations intervention: a meta-analysis of five clinical trials.
    Qian J; Chen Z; Ma J; Ge J
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):507-13. PubMed ID: 22045690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
    King L; Byrne RA; Mehilli J; Schömig A; Kastrati A; Pache J
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E23-8. PubMed ID: 22431239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.
    Kufner S; Byrne RA; de Waha A; Schulz S; Joner M; Laugwitz KL; Kastrati A;
    Cardiovasc Revasc Med; 2014 Mar; 15(2):69-75. PubMed ID: 24684757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital-(Research) Registry.
    Shen ZJ; García-García HM; Garg S; Onuma Y; Schenkeveld L; van Domburg RT; Serruys PW;
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):979-86. PubMed ID: 19753636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial.
    Desch S; Schloma D; Möbius-Winkler S; Erbs S; Gielen S; Linke A; Yu J; Lauer B; Kleinertz K; Dänschel W; Schuler G; Thiele H
    JACC Cardiovasc Interv; 2011 Apr; 4(4):452-9. PubMed ID: 21511226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of sirolimus-eluting stents vs. paclitaxel-eluting stents in unprotected left main coronary artery bifurcation lesions.
    Song PS; Ryu DR; Song YB; Hahn JY; Choi JH; Choi SH; Lee SH; Hong KP; Park JE; Gwon HC
    Clin Cardiol; 2011 Jun; 34(6):378-83. PubMed ID: 21538383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.